NASDAQ:GBT

Global Blood Therapeutics - GBT Stock Forecast, Price & News

$63.84

+15.85 (+33.03%)

(As of 08/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $46.57
▼
$73.02
50-Day Range: $22.30
▼
$63.84
52-Week Range: $21.65
▼
$73.02

Volume: 13.98 million shs
Average Volume: 1.37 million shs
Market Capitalization: $4.16 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.40

Global Blood Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 3.8% Downside
$61.40 Price Target
Short Interest: Healthy
14.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: 0.14
Based on 22 Articles This Week
Insider Trading: Selling Shares
$34,335 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.65) to ($3.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

1031st out of 1,283 stocks

Pharmaceutical Preparations Industry

486th out of 615 stocks

1.4

Analyst's Opinion

Consensus Rating
Global Blood Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $61.40, Global Blood Therapeutics has a forecasted downside of 3.8% from its current price of $63.84.
Amount of Analyst Coverage
Global Blood Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
14.95% of the float of Global Blood Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Global Blood Therapeutics has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Global Blood Therapeutics has recently decreased by 6.29%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Global Blood Therapeutics does not currently pay a dividend.
Dividend Growth
Global Blood Therapeutics does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Global Blood Therapeutics has received a 54.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other hematological medication (B06)", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Global Blood Therapeutics is -1.95.

2.9

News and Social Media Coverage

News Sentiment
Global Blood Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 22 news articles for Global Blood Therapeutics this week, compared to 2 articles on an average week.
Search Interest
23 people have searched for GBT on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.
MarketBeat Follows
6 people have added Global Blood Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Global Blood Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,335.00 in company stock.
Percentage Held by Insiders
Only 4.90% of the stock of Global Blood Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.65) to ($3.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Global Blood Therapeutics is -13.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Global Blood Therapeutics is -13.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Global Blood Therapeutics has a P/B Ratio of 20.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Global Blood Therapeutics (NASDAQ:GBT) Stock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Global Blood Therapeutics Price Performance

Shares of Global Blood Therapeutics stock opened at $63.84 on Friday. The company has a quick ratio of 7.74, a current ratio of 8.52 and a debt-to-equity ratio of 4.34. The firm's 50-day moving average price is $31.23 and its 200 day moving average price is $30.78. Global Blood Therapeutics has a twelve month low of $21.65 and a twelve month high of $73.02.

Global Blood Therapeutics (NASDAQ:GBT - Get Rating) last released its earnings results on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. The business had revenue of $55.20 million for the quarter, compared to analyst estimates of $56.13 million. During the same period last year, the company posted ($1.21) EPS. The business's revenue was up 41.5% on a year-over-year basis. On average, research analysts expect that Global Blood Therapeutics will post -4.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on GBT. JPMorgan Chase & Co. lowered their target price on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 28th. Cantor Fitzgerald began coverage on shares of Global Blood Therapeutics in a research note on Thursday, April 28th. They set a "buy" rating and a $75.00 target price on the stock. Oppenheimer lowered their target price on shares of Global Blood Therapeutics from $86.00 to $71.00 in a research note on Thursday, May 5th. Wedbush set a $74.00 target price on shares of Global Blood Therapeutics in a research note on Monday, June 20th. Finally, StockNews.com raised shares of Global Blood Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 5th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $61.40.

Insiders Place Their Bets

In other Global Blood Therapeutics news, Director Philip A. Pizzo sold 1,260 shares of the firm's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total value of $34,335.00. Following the transaction, the director now directly owns 9,112 shares of the company's stock, valued at approximately $248,302. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.90% of the company's stock.

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

August 7, 2022 | americanbankingnews.com

Global Blood Therapeutics (NASDAQ:GBT) Sees Large Volume Increase

August 6, 2022 | nasdaq.com

Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal

August 6, 2022 | americanbankingnews.com

Global Blood Therapeutics (NASDAQ:GBT) Sets New 52-Week High at $48.00

August 5, 2022 | reuters.com

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ